Skip to main content

edupression
at a glance

Everything about indication, area of application and evidence.

Digital therapy for depression1

edupression is a Class I digital medical device with CE marking. edupression is listed under MiGeL item number 40.01.01.00.1 with Pharmacode 1192679.

Subject to the applicable conditions, edupression is reimbursed by compulsory health insurance (OKP) upon a doctor’s prescription. The applicable limitations set out in the MiGeL are decisive.

ICD 10 codes: These indications can be treated with edupression

F32.0

Mild depressive episode


F32.1

Moderate depressive episode


F33.0

Recurrent depressive disorder, currently mild episode


F33.1

Recurrent depressive disorder, currently moderate episode

The German S3 guideline recommends for care in Germany the use of dGA (IMI, internet- and mobile-based interventions) as first-line therapy for mild depression. edupression can be used as a temporary measure until psychotherapy begins, or as a complement to ongoing psychotherapy.2

dGA in the treatment of depression

Added value for patients and practice

dGA in the
treatment of depression

Added value for patients and practice

Prompt start of therapy

edupression can serve as a therapeutic bridge until psychotherapy begins and can also be used to complement ongoing psychotherapy.

Treatment independent of time and place

With an internet-enabled device, depression therapy via dGA is always available when your patients need it.

Reimbursement via the OKP

Subject to the applicable conditions, edupression is reimbursed by compulsory health insurance (OKP) upon a doctor’s prescription. The applicable limitations set out in the MiGeL are decisive.

Proven effectiveness

The efficacy of edupression has been demonstrated in a randomized clinical trial. This makes the dGA edupression an effective treatment option for depression.

Therefore edupression

How edupression supports your treatment

In the eFICASY study, the effectiveness of edupression was investigated in comparison to a sham treatment (1:1 randomisation). The study demonstrated a significant reduction in depression severity (PHQ-9 score) and a significant improvement in depression competence through the use of edupression.3,4

Learn more

edupression contains comprehensible and visually appealing information texts, videos and quizzes to provide patients with comprehensive information about their illness. There are also numerous exercises, e.g. on breathing, mindfulness, resilience and acceptance, dealing with emotions and thoughts and progressive muscle relaxation.

edupression combines psychoeducation, CBT-based exercises and structured progress monitoring. The focus is on psychoeducation – it is part of all 59 edupression therapy sessions.
Among other things, edupression imparts knowledge about:

  • Development and influencing factors as well as symptoms and course of depression
  • Nervous system and stress reactions
  • Exercise and relaxation for depression
  • Therapy-resistant depression
  • Therapy options and antidepressant therapy

edupression includes CBT-based exercises and training sessions to apply the knowledge learned. edupression provides therapy feedback in the form of reports – e.g. on the PHQ-9 test, mood chart, therapy situation, learning overview and bipolarity.

Request test code

Testing edupression from the patient’s perspective

In order to explain the functionality and benefits of edupression to your patients in the best possible way, you have the opportunity to try out the digital therapy programme yourself. Our trial access gives you 3 days’ access to the edupression content as it is available to your patients.

To be able to use the test access, you need an individual access code. Simply request this using our form – we will send you the code by email within a short time.

Request test code

"*" indicates required fields

Title
Salutation
Name*
Practice address*
Email address*

Evidence

edupression – the effective, evidence-based treatment programme for depression

Digital health applications can complement the care of adults with depression. In Switzerland, edupression may be used, subject to the applicable conditions, as a bridging measure until psychotherapy begins or as a supplement to ongoing psychotherapy.1,2,5

edupression in clinical practice

To assess the use of edupression in everyday practice, a Vienna-based research group led by Prof. Lukas Pezawas conducted a retrospective analysis of data from the German NeuroTransData registry on the effectiveness, treatment adherence and user engagement of edupression.

Basis of the analysis

The analysis was based on data from 170 adult patients aged over 18 who were prescribed the DiGA for the first time as monotherapy or add-on therapy between 17 November 2023 and 1 May 2024. Three quarters (73%) were female and 47% had a recurrent depressive episode. 83% had moderate depression and 73% were receiving pharmacotherapy.6

PHQ-9 score

Between baseline and day 90, participants’ PHQ-9 scores improved by an average of 4.62 points. The data also showed that more frequent use of the DiGA was associated with greater improvement: in patients who used edupression more than twice a week, depression severity decreased by 5.32 PHQ-9 points, compared with 2.87 points in those who used it less often (< twice a week).6

Study design and population

The pivotal trial for edupression is the eFICASY trial. This prospective trial (German Clinical Trials Register (DRKS): DRKS00032121; ClinicalTrials.gov: NCT04839822) enrolled 250 patients aged 18 to 65 with mild to moderate depression (defined as PHQ-9* ≥ 5), who were randomised 1:1 to an intervention with edupression or to an active sham treatment (sham control).4

Control participants were given an app with an identical user interface and mood monitoring. However, the sham app contained no effective psychoeducational or psychotherapeutic content, only popular-psychology content with no proven effect as well as general health and relaxation tips.4 It is the only trial of a depression DiGA in which the control group received an app with an identical graphical interface.3

The primary endpoint of the eFICASY trial was depression severity at week 12. The primary analysis of the randomised controlled trial followed the intention-to-treat (ITT) principle.4

Use of edupression was associated with a statistically significant and clinically relevant advantage over the control group. By week 12, the PHQ-9 score in the intervention group decreased by 2.3 points (adjusted difference; 95% confidence interval [CI]: −3.5 to −1.0), significantly more than in the active control group (p < 0.001).4

In addition to depression severity, the eFICASY trial also assessed depression literacy (secondary endpoint), measured with the D-Lit questionnaire**. From baseline to week 12, depression literacy increased significantly more among edupression users than in the control group (adjusted D-Lit difference: 0.8; 95% CI: 0.2 to 1.4; p = 0.016).4 edupression is the only depression DiGA for which this healthcare effect has been officially recognised.3

Subgroup analyses also showed that the treatment effects were consistent across age, sex and depression severity, as well as with or without psychopharmacotherapy and psychotherapy.4

What our depression specialists say

Dr Harsha Buksh

Psychiatrist

edupression strengthens
my therapy.

I have been looking for a long time to find a digital medical product in the field of depression that meets my expectations. edupression succeeds in every respect.

Dr Emmalynn Mazzia

Psychologist

I can also observe my clients’ progress between two therapy sessions.

The content is very informative and practice-orientated. Thanks to edupression, I can also get a good picture in the time between therapy sessions.

Dr Beth Murphy

Psychiatrist

My patients love edupression.

edupression offers my patients top-class content – exciting, informative and evidence-based; they simply love it!

Patient cases

As a cooperation partner of edupression, SERVIER provides helpful information material on digital depression therapy – including several patient cases inspired by practice. The cases are available for download at a central location on the MyServier specialist portal.

About MyServier

References/Sources:

* PHQ-9: Patient Health Questionnaire-9
** D-Lit: Depression Literacy Questionnaire

  1. EUDAMED Verzeichnis https://ec.europa.eu/tools/eudamed/
  2. German S3 guideline: National Disease Management Guideline Unipolar Depression (Nationale VersorgungsLeitlinie Unipolare Depression), version 3.2, 2022, AWMF, register no. nvl-005
  3. Kaminski J, Machleid F, Wiegmann C, et al. (2025) Digitale Gesundheitsanwendungen für depressive Störung in Deutschland [Digital health applications for depressive disorders in Germany: a narrative review of the evidence and integration into treatment]. Nervenarzt 96:432–438. https://doi.org/10.1007/s00115-025-01879-7
  4. Preiß M, et al. (2023) Randomized controlled clinical trial of the efficacy of the digital self-help program edupression.com® in mild-to-moderate unipolar depressive patients (eFICASY-study). Neuroscience Applied 2:103615 (abstract, ECNP Congress 2023). https://doi.org/10.1016/j.nsa.2023.103615
  5. NICE guideline: Depression in adults – treatment and management, 2022; https://www.nice.org.uk/guidance/ng222
  6. Symposium “Affektive Erkrankungen: therapeutische Interventionen” [Affective disorders: therapeutic interventions], DGPPN Congress, 27 November 2024, Berlin